J Cell Mol Med. 2023 Sep;27(18):2730-2743.doi: 10.1111/jcmm.17860. Epub 2023 Jul 21.

中文速读

本研究针对胶质瘤,使用Entranster-R4000将siRNA转染至A172和U87细胞敲低PKN1,并利用腺病毒过表达PKN1,发现PKN1通过调控YAP促进胶质瘤恶性进展,且雷洛昔芬靶向PKN1抑制肿瘤并增强TMZ敏感性。

体外(细胞)siRNA质粒DNAA172U87LN229

本文使用:小核酸转染试剂Entranster™-R4000

查看产品详情(含全部 223 篇文献) →

The role of PKN1 in glioma pathogenesis and the antiglioma effect of raloxifene targeting PKN1

Affiliations

Affiliations

  • 1 Department of Neurosurgery, Tianjin Medical University General Hospital. Tianjin Neurological Institute, Laboratory of Neuro-Oncology, Key Laboratory of Post-Trauma Neuro-Repair and Regeneration in Central Nervous System, Ministry of Education. Tianjin Key Laboratory of Injuries, Variations and Regeneration of Nervous System, Tianjin, P. R. China.
  • 2 Clinical College of Neurology, Neurosurgery and Neurorehabilitation Tianjin Medical University, Tianjin, P. R. China.
  • 3 Laboratory of Neuro-Chemistry, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China.
  • 4 Department of Neurosurgery, Tianjin Huanhu Hospital, Tianjin, China.

Abstract

PKN1 (protein kinase N1), a serine/threonine protein kinase family member, is associated with various cancers. However, the role of PKN1 in gliomas has rarely been studied. We suggest that PKN1 expression in glioma specimens is considerably upregulated and positively correlates with the histopathological grading of gliomas. Knocking down PKN1 expression in glioblastoma (GBM) cells inhibits GBM cell proliferation, invasion and migration and promotes apoptosis. In addition, yes-associated protein (YAP) expression, an essential effector of the Hippo pathway contributing to the oncogenic role of gliomagenesis, was also downregulated. In contrast, PKN1 upregulation enhances the malignant characteristics of GBM cells and simultaneously upregulates YAP expression. Therefore, PKN1 is a promising therapeutic target for gliomas. Raloxifene (Ralo), a commonly used selective oestrogen-receptor modulator to treat osteoporosis in postmenopausal women, was predicted to target PKN1 according to the bioinformatics team from the School of Mathematics, Tianjin Nankai University. We showed that Ralo effectively targets PKN1, inhibits GBM cells proliferation and migration and sensitizes GBM cells to the major chemotherapeutic drug, Temozolomide. Ralo also reverses the effect of PKN1 on YAP activation. Thus, we confirm that PKN1 contributes to the pathogenesis of gliomas and may be a potential target for Ralo adjuvant glioma therapy.

Keywords: GBM; PKN1; TMZ; YAP; raloxifene.

本文使用的产品

小核酸转染试剂Entranster™-R4000

已有 223 篇已发表文献

查看产品详情(含全部 223 篇文献) →

热线电话
  • 010-60535354
微信客服二维码 微信扫一扫,加微信客服
0
0
我的购物车
购物车是空的去下单